2023
Diagnosis and Classification of Myelodysplastic Syndromes with Mutated TP53
Siddon A, Weinberg O. Diagnosis and Classification of Myelodysplastic Syndromes with Mutated TP53. Clinics In Laboratory Medicine 2023, 43: 607-614. PMID: 37865506, DOI: 10.1016/j.cll.2023.07.004.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMyelodysplastic syndromeTP53 mutationsPrognosis of MDSCases of MDSPrognostic scoring systemNext-generation sequencingParticular next-generation sequencingAggressive diseasePoor outcomeTherapeutic managementTP53 disruptionMyeloid leukemiaMyeloid neoplasmsTherapeutic advancementsCytogenetic abnormalitiesMyeloid neoplasiaScoring systemDisease classificationMyeloid diseasesGene mutationsSyndromeDiseaseDiagnosisTP53Molecular Techniques and Gene Mutations in Myelodysplastic Syndromes
Mendoza H, Siddon A. Molecular Techniques and Gene Mutations in Myelodysplastic Syndromes. Clinics In Laboratory Medicine 2023, 43: 549-563. PMID: 37865502, DOI: 10.1016/j.cll.2023.06.002.Peer-Reviewed Original ResearchMyeloid sarcoma with NPM1 mutation may be clinically and genetically distinct from AML with NPM1 mutation: a study from the Bone Marrow Pathology Group
de M, Wu L, Hirt C, Pihan G, Patel S, Tam W, Bueso-Ramos C, Kanagal-Shamanna R, Raess P, Siddon A, Narayanan D, Morgan E, Pinkus G, Mason E, Hsi E, Rogers H, Toth L, Foucar K, Hurwitz S, Bagg A, Rets A, George T, Orazi A, Arber D, Hasserjian R, Weinberg O, Group F. Myeloid sarcoma with NPM1 mutation may be clinically and genetically distinct from AML with NPM1 mutation: a study from the Bone Marrow Pathology Group. Leukemia & Lymphoma 2023, 64: 972-980. PMID: 36960680, DOI: 10.1080/10428194.2023.2185091.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMyeloid sarcomaOverall survivalNPM1 mutationsDe novo acute myeloid leukemiaBone Marrow Pathology GroupMulti-institutional cohort studyNovo acute myeloid leukemiaRetrospective multi-institutional cohort studyShorter overall survivalPoor overall survivalFrequent cytogenetic abnormalityCohort studyMyeloid leukemiaPathology groupCytogenetic abnormalitiesComplex karyotypeUnique genetic landscapeMutations of genesGene mutationsSarcomaGenetic landscapeHigher average numberMutationsLeukemia
2022
NPM1 mutations may be associated with adverse outcome in the setting of myeloid neoplasms with complex karyotype
Ramia de Cap M, Wu L, Pihan G, Narayanan D, Morgan E, Pinkus G, Cin P, Hurwitz S, Bagg A, Patel S, Tam W, Ouseph M, Gagan J, Madanat Y, Siddon A, Raess P, Rogers H, Bueso-Ramos C, Kanagal-Shamanna R, Kurzer J, Arber D, Hasserjian R, Weinberg O. NPM1 mutations may be associated with adverse outcome in the setting of myeloid neoplasms with complex karyotype. Leukemia Research 2022, 123: 106965. PMID: 36332291, DOI: 10.1016/j.leukres.2022.106965.Peer-Reviewed Original ResearchTP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML
Weinberg OK, Siddon A, Madanat Y, Gagan J, Arber DA, Dal Cin P, Narayanan D, Ouseph MM, Kurzer JH, Hasserjian RP. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML. Blood Advances 2022, 6: 2847-2853. PMID: 35073573, PMCID: PMC9092405, DOI: 10.1182/bloodadvances.2021006239.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMyelodysplastic syndromeOverall survivalTP53 mutationsComplex karyotypeBlast countWorse outcomesTherapy-related MDS/acute myeloid leukemiaDiagnosis of AMLMDS/acute myeloid leukemiaTherapy-related myeloid neoplasmsTherapy-related casesTP53-mutated patientsDe novo diseaseMarrow blast countLower hemoglobin levelsWorse overall survivalCK patientsNovo diseaseDifferent disease categoriesClinicopathologic featuresHemoglobin levelsMDS patientsMultivariable analysisAggressive disease
2020
A case of acute myeloid leukemia with unusual germline CEBPA mutation: lessons learned about mutation detection, location, and penetrance
Mendoza H, Chen PH, Pine AB, Siddon AJ, Bale AE, Gowda L, Killie A, Richards J, Varin-Tremblay C, Kloss R, Podoltsev NA. A case of acute myeloid leukemia with unusual germline CEBPA mutation: lessons learned about mutation detection, location, and penetrance. Leukemia & Lymphoma 2020, 62: 1251-1254. PMID: 33345654, DOI: 10.1080/10428194.2020.1861276.Peer-Reviewed Case Reports and Technical NotesIsolated trisomy 11 in patients with acute myeloid leukemia – is the prognosis not as grim as previously thought?*
Bewersdorf JP, Shallis RM, Diadamo A, Gowda L, Podoltsev NA, Siddon A, Zeidan AM. Isolated trisomy 11 in patients with acute myeloid leukemia – is the prognosis not as grim as previously thought?*. Leukemia & Lymphoma 2020, 61: 2254-2257. PMID: 32338096, PMCID: PMC7485109, DOI: 10.1080/10428194.2020.1755858.Peer-Reviewed Original Research
2018
Morphology and flow cytometry of atypical basophils
Tormey CA, Siddon AJ. Morphology and flow cytometry of atypical basophils. Blood 2018, 132: 552. PMID: 30072417, DOI: 10.1182/blood-2018-05-850073.Peer-Reviewed Original Research
2015
Hemoglobinopathy Screening in a 15-Year-old Patient With Anemia
Honarpisheh H, Hogan M, Rinder HM, Siddon AJ. Hemoglobinopathy Screening in a 15-Year-old Patient With Anemia. Journal Of Pediatric Hematology/Oncology 2015, 37: 472-473. PMID: 26181419, DOI: 10.1097/mph.0000000000000357.Peer-Reviewed Case Reports and Technical Notes
2013
Pathology Consultation on Evaluating Prognosis in Incidental Monoclonal Lymphocytosis and Chronic Lymphocytic Leukemia
Siddon AJ, Rinder HM. Pathology Consultation on Evaluating Prognosis in Incidental Monoclonal Lymphocytosis and Chronic Lymphocytic Leukemia. American Journal Of Clinical Pathology 2013, 139: 708-712. PMID: 23690112, DOI: 10.1309/ajcplir4gzwx3xka.Peer-Reviewed Original ResearchMeSH KeywordsADP-ribosyl Cyclase 1Beta 2-MicroglobulinFlow CytometryGene Rearrangement, B-LymphocyteHumansImmunoglobulin Heavy ChainsImmunoglobulin Variable RegionIncidental FindingsLeukemia, Lymphocytic, Chronic, B-CellLymphocytosisMaleMiddle AgedMutationPrognosisWatchful WaitingZAP-70 Protein-Tyrosine KinaseConceptsChronic lymphocytic leukemiaEarly-stage chronic lymphocytic leukemiaStage chronic lymphocytic leukemiaDisease progressionLymphocytic leukemiaImmunoglobulin heavy chain variable (IGHV) gene mutational statusMonoclonal B-cell lymphoproliferative disorderLaboratory evaluationOvert chronic lymphocytic leukemiaMonoclonal B-cell lymphocytosisB-cell lymphoproliferative disordersAggressive disease progressionSignificant disease progressionIndolent clinical courseSerum β2-microglobulinRoutine laboratory evaluationB-cell lymphocytosisZAP-70 expressionGene mutational statusMonoclonal lymphocytosisClinical courseExpectant observationLymphoproliferative disordersTherapeutic optionsPrognostic marker
2012
Normalized CCND1 expression has prognostic value in mantle cell lymphoma
Siddon AJ, Torres R, Rinder HM, Smith BR, Howe JG, Tormey CA. Normalized CCND1 expression has prognostic value in mantle cell lymphoma. British Journal Of Haematology 2012, 158: 551-553. PMID: 22671703, DOI: 10.1111/j.1365-2141.2012.09181.x.Peer-Reviewed Original Research